GlassScriptPhysician profile
Michelle L Aliotta
NPI 1972877785
$945.35
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.64 · 2020: $125 · 2021: $71.26 · 2022: $416 · 2023: $247 · 2024: $41.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.72 | 2021-2023 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $163.70 | 2022-2024 | Mounjaro |
| Allergan, INC. | $124.82 | 2020 | |
| Novo Nordisk INC | $58.73 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $48.80 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.41 | 2023-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $44.26 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.71 | 2023 | |
| Pfizer INC. | $38.72 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.24 | 2022 | |
| Itamar Medical INC | $18.31 | 2023 | Watchpatone |
| Amarin Pharma, INC. | $14.89 | 2023 | |
| Glaxosmithkline, LLC. | $13.61 | 2019 | |
| Lundbeck LLC | $13.21 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $12.95 | 2023 | Belsomra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Aliotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.